IRIS
CAROTENUTO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.069
NA - Nord America 5.434
EU - Europa 4.058
SA - Sud America 736
Continente sconosciuto - Info sul continente non disponibili 373
AF - Africa 162
OC - Oceania 17
Totale 16.849
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.135
SG - Singapore 2.505
RU - Federazione Russa 1.637
CN - Cina 1.245
VN - Vietnam 1.093
IT - Italia 999
BR - Brasile 553
HK - Hong Kong 507
DE - Germania 399
FR - Francia 206
NL - Olanda 196
CA - Canada 188
IN - India 145
GB - Regno Unito 129
JP - Giappone 113
FI - Finlandia 107
KR - Corea 86
IE - Irlanda 83
BD - Bangladesh 80
UA - Ucraina 74
AR - Argentina 66
ZA - Sudafrica 53
MX - Messico 46
ES - Italia 39
CI - Costa d'Avorio 38
PH - Filippine 38
PL - Polonia 36
SE - Svezia 36
TH - Thailandia 35
IQ - Iraq 33
EC - Ecuador 32
ID - Indonesia 28
TR - Turchia 27
AT - Austria 23
CO - Colombia 21
VE - Venezuela 21
LT - Lituania 19
PK - Pakistan 18
TW - Taiwan 16
BE - Belgio 15
JM - Giamaica 15
SA - Arabia Saudita 15
CL - Cile 13
JO - Giordania 13
MA - Marocco 12
MY - Malesia 12
PY - Paraguay 12
TN - Tunisia 12
CZ - Repubblica Ceca 10
NP - Nepal 10
AE - Emirati Arabi Uniti 9
CR - Costa Rica 9
EG - Egitto 8
KE - Kenya 8
PE - Perù 8
AU - Australia 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
NI - Nicaragua 7
NZ - Nuova Zelanda 6
BO - Bolivia 5
ET - Etiopia 5
GR - Grecia 5
GT - Guatemala 5
IR - Iran 5
MK - Macedonia 5
PT - Portogallo 5
RS - Serbia 5
AM - Armenia 4
BG - Bulgaria 4
HN - Honduras 4
HR - Croazia 4
IL - Israele 4
MN - Mongolia 4
OM - Oman 4
PA - Panama 4
AL - Albania 3
BB - Barbados 3
CU - Cuba 3
LV - Lettonia 3
MD - Moldavia 3
SV - El Salvador 3
UY - Uruguay 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
CH - Svizzera 2
GA - Gabon 2
GD - Grenada 2
GE - Georgia 2
GY - Guiana 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
QA - Qatar 2
RE - Reunion 2
SC - Seychelles 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 16.448
Salva come PNG Salva come JPEG
Città #
Singapore 1.240
San Jose 1.027
Ashburn 539
Hong Kong 476
Moscow 424
Hefei 401
Beijing 330
Ho Chi Minh City 327
Chandler 309
Hanoi 252
Santa Clara 252
Naples 216
Council Bluffs 198
Los Angeles 167
Amsterdam 145
Lauterbourg 110
Tokyo 104
The Dalles 96
Munich 87
Dallas 80
New York 80
Millbury 77
Seoul 69
São Paulo 66
Milan 65
Phoenix 59
Buffalo 57
Des Moines 57
Boston 52
Da Nang 50
Napoli 50
Redondo Beach 49
Montreal 48
Denver 43
Frankfurt am Main 41
Seattle 40
Nanjing 39
Rome 39
Haiphong 37
Helsinki 37
Princeton 37
Lawrence 36
Chicago 35
Toronto 34
Krefeld 33
Orem 32
Dublin 31
Warsaw 29
Johannesburg 28
Norwalk 28
Atlanta 26
London 26
Stockholm 26
Dong Ket 24
Falkenstein 24
Houston 24
Turku 23
Brooklyn 22
Chennai 22
Mexico City 19
Nuremberg 19
San Francisco 18
Wilmington 18
Lappeenranta 17
Pune 17
Tianjin 17
Boardman 16
Rio de Janeiro 16
Biên Hòa 15
Ottawa 15
Poplar 15
Rottweil 15
Baghdad 14
Curitiba 14
Düsseldorf 14
Paris 14
Bangkok 13
Can Tho 13
Kingston 13
Ankara 12
Bari 12
Belo Horizonte 12
Cava De' Tirreni 12
Mumbai 12
Thái Nguyên 12
Catania 11
Manchester 11
Quito 11
Amman 10
Brasília 10
Bến Tre 10
Charlotte 10
Hải Dương 10
Kolkata 10
Shanghai 10
Brussels 9
Formia 9
Guayaquil 9
Istanbul 9
Nanchang 9
Totale 8.907
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 284
Uric acid: a potential biomarker of multiple sclerosis and of its disability 212
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 204
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 194
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 178
The use of medical-grade cannabis in patients non-responders to Nabiximols 171
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 169
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 169
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 168
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 168
Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis 167
The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study 164
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 163
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 162
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 159
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 158
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 158
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 154
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 154
Inhibition of oligodendrocyte differentiation by immunoglobulin purified from serum of multiple sclerosis patients during relapse 153
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 152
Prevalence and Incidence of Paramagnetic Rim Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis 152
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 152
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 150
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 150
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 149
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 148
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(®) 148
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 148
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 147
A real-world study of alemtuzumab in a cohort of Italian patients 147
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 147
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 147
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 147
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 147
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 147
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 147
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy 146
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 146
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 145
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 143
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis 143
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 143
Biochemical parameters alterations in multiple sclerosis: a longitudinal study and review of the literature. 143
Retinal vascular density in multiple sclerosis: a one year follow up 141
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 141
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 140
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 140
Exploring the relation between reserve and fatigue in multiple sclerosis 137
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 137
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 135
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 135
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 135
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 134
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 132
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 132
Dysphagia assessment in patients with multiple sclerosis - an additional piece to disability burden 131
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 131
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 131
Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition 130
Correction to: Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 129
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 126
Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis 126
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 126
Integration of the expanded disability status scale with ambulation, visual and cognitive tests 124
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years 124
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 124
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 124
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 124
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study 124
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. 123
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 122
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 122
Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence 121
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 121
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 121
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis 118
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 118
Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data 118
Anatomical and functional retinal changes in multiple sclerosis 117
A longitudinal real-life comparison study of natalizumab and fingolimod 116
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 116
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis 114
Can people with multiple sclerosis actually understand what they read in the Internet age? 113
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 113
Association between CD20+ T lymphocytes and neuropsychological findings in multiple sclerosis 112
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 111
A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis 111
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 111
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 111
Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis 108
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 107
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 107
Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia 105
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy 105
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials 104
Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, sex, and education 104
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications 100
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 100
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy) 99
Totale 13.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.133
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.133
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022458 0 0 4 6 11 36 8 17 58 34 105 179
2022/20231.000 81 87 20 43 87 125 152 53 152 132 45 23
2023/2024678 32 96 84 56 41 85 17 71 21 17 101 57
2024/20254.047 182 179 32 72 132 251 432 279 246 431 1.414 397
2025/20268.761 836 743 888 908 1.474 291 884 613 1.057 631 244 192
2026/2027968 223 493 252 0 0 0 0 0 0 0 0 0
Totale 16.849